Trial Profile
A phase II trial on efficacy and safety of osimertinib in elderly EGFR T790M-positive non-small-cell lung cancer patients who progressed during prior EGFR-TKI treatment or had recurrence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPIRAL Study
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 05 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2018 Trial design published in the Medicine.